Abstract
IgA nephropathy (IgAN) is an autoimmune disorder that commonly manifests during adolescence. This disease is believed to be a non-monogenic disorder related to variations in multiple genes involved in various biological pathways.
We performed the exome-wide association study of 70 children with IgAN confirmed by renal biopsy and 637 healthy donors to identify gene associations responsible for the disease. The HLA allele frequencies between the patients and healthy donors from the bone marrow registry of the Pirogov University were compared. We tested 78,020 gene markers for association, performed the functional enrichment analysis and the transcription factor binding preference detection.
We detected 333 genetic variants, employing three inheritance models. The most significant association with the disorder was observed for rs143409664 (PRAG1) in case of the additive and dominant models (PBONF = 1.808 × 10−15 and PBONF = 1.654 × 10−15, respectively) and for rs13028230 (UBR3) in case of the recessive model (PBONF = 1.545 × 10−9). Enrichment analysis indicated the strongly overrepresented “immune system” and “kidney development” terms. The HLA-DQA1*01:01:01G allele (P = 0.0076; OR, 2.021 [95% CI, 1.322-3.048]) was significantly the most frequent among IgAN patients.
Here we characterized, for the first time, the genetic background of the Russian IgAN patients identifying the risk alleles typical of the population. The most prominent signals were detected in previously undescribed loci.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by grant 075-15-2019-1789 from the Ministry of Science and Higher Education of the Russian Federation allocated to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All legal representatives as well as patients over 15 y.o. signed the appropriate informed voluntary consent to participate in the study. Local ethics committee of Pirogov Russian National Research Medical University approved this study on the 17th of December, 2018 (Protocol No. 181).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes